Intravitreal triamcinolone for refractory pseudophakic macular edema - 28/08/11
, Pascale Massin, MD, PhD a, Belkacem Haouchine, MD a, Francois Audren, MD a, Ramin Tadayoni, MD a, Alain Gaudric, MD aAbstract |
Purpose |
To evaluate the efficacy of intravitreal triamcinolone in refractory pseudophakic cystoid macular edema.
Design |
A prospective, interventional case series.
Methods |
Three eyes of three patients with longstanding pseudophakic cystoid macular edema following uncomplicated cataract surgery, refractory to any medication, were treated with 8 mg of intravitreal triamcinolone. All three eyes were evaluated before injection and throughout follow-up with the Early Treatment Diabetic Retinopathy Study’s visual acuity chart, fluorescein angiography, and macular mapping using optical coherence tomography.
Results |
A month after intravitreal triamcinolone injection, a dramatic decrease in macular thickness was noted by optical coherence tomography in all three eyes (from a mean of 502–233 μm). Mean improvement in visual acuity was 3.7 Snellen lines. Two to 4 months after triamcinolone injection, however, the edema recurred in all cases, to the same degree as before the injection, combined with a decrease in vision. Two eyes underwent a second injection of triamcinolone, and macular thickness decreased, but the edema again recurred 3 months after injection.
Conclusion |
Intravitreal injection of triamcinolone induces striking regression, within 1 month, of chronic refractory macular edema. This regression appears to be transient, however, even after a second injection.
Le texte complet de cet article est disponible en PDF.
Vol 135 - N° 2
P. 246-249 - février 2003 Retour au numéro
Article précédent
- Submacular deposition of triamcinolone acetonide after triamcinolone-assisted vitrectomy
- Hiroshi Enaida, Taiji Sakamoto, Akifumi Ueno, Takao Nakamura, Yoshihiro Noda, Keiko Maruoka, Tatsuro Ishibashi
- Ocular tilt reaction due to a mesencephalic lesion in juvenile polyarteritis nodosa
- Nicola K. Ragge, Christopher M. Harris, Michael J. Dillon, W.Kling Chong, J. Elston, David S.I. Taylor
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?